-
Mashup Score: 8European Society for Medical Oncology 2023 Annual Meeting (ESMO 2023) Conference Coverage - 1 year(s) ago
Original content by clinicians, featuring conference coverage, video lectures, and editor commentaries.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Out of the Basement and Into the Classroom: Pathways for Expanding the Role of Radiation Oncologists in Medical Student Education - PubMed - 1 year(s) ago
The minority of RO departments are involved in formal teaching of the medical student body at large. The approaches described herein should facilitate more robust involvement of radiation oncologists in all areas of undergraduate medical education.
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues - 1 year(s) ago
Not everyone loses weight on Ozempic-type drugs. Researchers are looking for genetic clues to steer patients more accurately.
Source: www.statnews.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Progress depends on fully engaging people and communities in improving health and care With a general election in prospect, and opinion polls showing the Labour Party well ahead of the Conservatives, attention is turning to Labour’s plans for health and social care. In his speech last week, Labour’s shadow health secretary, Wes Streeting, reiterated his party’s mission as “to get the NHS back on its feet and fit for the future.”1 He acknowledged that achieving this mission would take time, investment, and reform, adding that reform is more important than investment. He might have added, but didn’t, that time is even more important. More specifically, Streeting identified three shifts that are needed: from hospital to community, from analogue to digital, and from sickness to prevention. He also emphasised that there is no solution to the crisis in the NHS that doesn’t include a plan for social care, promising to deliver a 10 year plan for health and social care. Notably absent from the
Source: www.bmj.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the survival rate of children with ALL. In the past two decades, the use of minimal (measurable) residual disease (MRD) measurements early in therapy improved risk group stratification with subsequent treatment intensifications for patients at high risk of relapse, and enabled a reduction of treatment for low-risk patients. The recent development of more sensitive MRD technologies may further affect risk stratification. Molecular genetic profiling has led to the discovery of many new subtypes and their driver genetic alterations. This increased our understanding of the biological basis of ALL, improved risk classification, and enabled implementation of precision medicine. In the past decade, immunotherapies, including bispecific antibodies, antibody-drug conjugates, and cellular therapies directed against surface proteins, led to more effective and less toxic therapies, replacing intensive chemotherapy co
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6
Nature – Treatment with the oncolytic herpes virus CAN-3110 is associated with improved survival responses in patients with recurrent glioblastoma, particularly in individuals who are seropositive…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Re-activating the immune system against cancer: The next I-O revolution - Endpoints Webinars - 1 year(s) ago
Patients dealing with cancers that have resisted immuno-oncology (IO) therapies potentially have a new treatment option on the horizon. More than a decade after the first checkpoint inhibitor raised hopes, next-generation investigational IO is lighting up clinics with long-sought encouraging results against the persistent “cold” tumors involved in colorectal, lung,
Source: webinars.endpts.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Sickle cell disease is the most common inherited pathological haemoglobinopathy. Over the past 30 years, disease-related morbidity and mortality have …
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Glücksklee, the Quad, and High-Risk Myeloma - 1 year(s) ago
In the article that accompanies this editorial, Leypoldt et al 1 describe the results of a forward-thinking study focused on the management of high-risk newly diagnosed multiple myeloma (HR NDMM) using the quadruplet (quad) regimen: isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd). This multicenter, phase II trial enrolled patients with HR NDMM, cytogenetically defined as the presence of del17p, t(4;14), t(14;16), or more than three copies of 1q21. Patients were not eligible if they had
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3The OncoAlert Newsletter is NOW OUT Click to Register - 1 year(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Hem/Oncs, Latest HeadlinesTweet
Looking forward to #ESMO23 presentation by @drlouiseemmett LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, #mCRPC: a randomized, phase 2 trial: ENZA-p (ANZUP 1901). Visit UroToday for written coverage throughout the conference > https://bit.ly/3FmeO68 @ANZUPtrials @myESMO